Analysts Issue Forecasts for ANIX Q1 Earnings

Anixa Biosciences Inc (NASDAQ:ANIX) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Anixa Biosciences in a research report issued to clients and investors on Thursday, June 11th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Anixa Biosciences’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Anixa Biosciences’ Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.31) EPS.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03.

Other equities analysts have also recently issued research reports about the company. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Anixa Biosciences presently has a consensus rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.50 on Friday. The stock has a 50-day simple moving average of $2.78 and a 200-day simple moving average of $3.10. The stock has a market capitalization of $83.83 million, a PE ratio of -8.06 and a beta of 0.59. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new position in Anixa Biosciences in the second quarter valued at approximately $33,000. Cetera Investment Advisers purchased a new position in Anixa Biosciences in the fourth quarter valued at approximately $35,000. Northwestern Mutual Wealth Management Co. increased its stake in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences in the second quarter valued at approximately $37,000. Finally, Millennium Management LLC purchased a new position in Anixa Biosciences in the fourth quarter valued at approximately $38,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.